

Rituxan (Rheumatoid Arthritis) Forecast and Market Analysis

Description: Rituxan (Rheumatoid Arthritis) Forecast and Market Analysis

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, Rituxan (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer's Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly's anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ's SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market.

Rituxan was co-developed and marketed in the US (under the brand name Rituxan) by Biogen Idec and Genentech (now a part of Roche). It is marketed outside of the US by Roche under the brand name MabThera. Rituxan was initially approved for the treatment of lymphoma and it was the first mAb to be approved for the treatment of cancer. In 2006, Rituxan was approved in the US and 5EU for the treatment of moderate to severe active RA in patients who do not adequately respond to one or more TNF inhibitors.

Scope

- Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Rituxan including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Rituxan for the top nine countries from 2012 to 2022.
- Sales information covered for the US, Japan, UK, France, Germany, Spain, Italy, India and Australia

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Rituxan performance
- Obtain sales forecast for Rituxan from 2011-2022 in the US, Japan, UK, France, Germany, Spain, Italy, India and Australia

Contents:

1
1
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Prognosis
3.1.4 Quality of Life
3.2 Symptoms
4 Disease Management
4.1 Overview
4.2 Diagnosis

- 4.3 Treatment
- 5 Competitive Assessment
- 5.1 Overview
- 5.2 Strategic Competitor Assessment
- 6 Product Profile - Rituxan/MabThera (rituximab)
- 6.1 Overview
- 6.2 Efficacy
- 6.3 Safety
- 6.4 SWOT Analysis
- 6.5 Forecast
- 7 Appendix
- 7.1 Abbreviations
- 7.2 Bibliography
- 7.3 Methodology
- 7.4 Forecasting Methodology
- 7.4.1 Diagnosed Rheumatoid Arthritis Patients
- 7.4.2 Percent Drug-treated Patients
- 7.4.3 General Pricing Assumptions
- 7.4.4 Individual Drug Assumptions
- 7.5 Physicians and Specialists Included in this Study
- 7.6 Primary Research - Prescriber Survey
- 7.7 About the Authors
- 7.7.1 Analysts
- 7.7.2 Global Head of Healthcare
- 7.8 About Us
- 7.9 Contact Us
- 7.10 Disclaimer

1.1 List of Tables

- Table 1: Symptoms of Rheumatoid Arthritis
- Table 2: Treatment Guidelines for Rheumatoid Arthritis
- Table 3: Top Three Biologics Prescribed for Moderate-Severe Rheumatoid Arthritis by Market
- Table 4: Treatment Guidelines for Rheumatoid Arthritis
- Table 5: Product Profile - Rituxan
- Table 6: Rituxan SWOT Analysis, 2012
- Table 7: Global Sales Forecasts (\$m) for Rituxan
- Table 8: Physicians Surveyed, By Country

1.2 List of Figures

- Figure 1: Healthy and Arthritic Joint with Rheumatoid Arthritis
- Figure 2: Rheumatoid Arthritis Biologic Drug Targets
- Figure 3: Diagnosis Criteria for Rheumatoid Arthritis Based on 2010 ACR/EULAR Criteria Point System
- Figure 4: Severity of Rheumatoid Arthritis
- Figure 5: Biologic Treatment Flow Based on Updated 2012 ACR Treatment Recommendations-

Ordering: Order Online - <http://www.researchandmarkets.com/reports/2383163/>

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit

<http://www.researchandmarkets.com/contact/>

Order Information

Please verify that the product information is correct and select the format(s) you require.

Product Name: Rituxan (Rheumatoid Arthritis) Forecast and Market Analysis
Web Address: <http://www.researchandmarkets.com/reports/2383163/>
Office Code: SC9C9ZKX

Product Formats

Please select the product formats and quantity you require:

	Quantity	
Electronic (PDF) - Single User:	<input type="checkbox"/>	USD 3495
Electronic (PDF) - Site License:	<input type="checkbox"/>	USD 6990
Electronic (PDF) - Enterprisewide:	<input type="checkbox"/>	USD 10485

Contact Information

Please enter all the information below in **BLOCK CAPITALS**

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____ Last Name: _____

Email Address: * _____

Job Title: _____

Organisation: _____

Address: _____

City: _____

Postal / Zip Code: _____

Country: _____

Phone Number: _____

Fax Number: _____

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)

Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

- Pay by credit card:
 - American Express
 - Diners Club
 - Master Card
 - Visa

Cardholder's Name _____

Cardholder's Signature _____

Expiry Date _____ | _____

Card Number _____

CVW Number _____

Issue Date _____ | _____

(for Diners Club only)

- Pay by check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

- Pay by wire transfer:

Please transfer funds to:

Account number	833 130 83
Sort code	98-53-30
Swift code	ULSBIE2D
IBAN number	IE78ULSB98533083313083
Bank Address	Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _____

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at <http://www.researchandmarkets.com/info/terms.asp>

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World